Blog / Archives
NASDAQ Rolls On To 10 Year High At 3016 Up 1%
Biotech Sector (IBB $119.73) Up 12 % YTD, Lagging NASDAQ (QQQ) Up 17.85% Here is a summary of our recommendations over the past month: No change in our basic Rayno Life Science...
Snow Blog West: Snowy Period by March 17th
All the Models Looking Better for PPT We should see a change by next weekend for one of the worst Sierra seasons in recent times. Mammoth has a good base due to excellent man made snow, but has...
Biotech Stocks Ignited on JNJ Prostate Drug Study
Biotech Sector Recovers from Monday's Weakness-Bull Intact Biotech stocks are strong today tracking a NASDAQ rally and favorable news on JNJ's prostate drug Zytiga which met its goal in a new study....
Illumina (ILMN $50.35) Good Value
CEO Jay Flatley was on CNBC at 4:55p today with Maria Bartiromo. Maria asked him why the Company did not accept the Roche offer? He answered " because the offer was near the stock's low for the...
Sell-Off Picks Up With Some Biotechs Hit Hard
Smaller Cap Biotechs In Major Correction All the major indices are down in the 1.75% range and now the NASDAQ at 2902 is 100 pts. away from the elusive 3000 level. Analysts have been warning about...
Caution Rules: Easy Money Has Been Made With Biotech Up 15% YTD
Pause Mode Since February 15 The biotech indices and ETF's we track are off about 1% or more today as the market is in a profit taking mode. The Rayno Life Science Portfoio is also off about 1%....
Biotech Bull Market Intact But Due For A Pause
Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over...
Another Daily Reversal : Take More Off in Biotech
Have you read the book "Think Fast,Think Slow" by Daniel Kahneman? Well my System 1 (fast, intuitive and emotional) brain sees a lot of red on the screen telling me to take profits. If you want...
Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen
$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with...
No Panic Just Take A Little Off:Caution- Update Rally 2/16
Market Reversal and a Light Sell-Off Technicals and a market reversal particularly a $20+ drop in AAPL gives us reason to take profits or hedge after a great start to 2012. The S&P is up 7%...